☆ 4.5 Letter

Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis

CANCER COMMUNICATIONS (2020)

Get Full Text
Add to Collection

Journal

CANCER COMMUNICATIONS
Volume 40, Issue 12, Pages 743-745

Publisher

WILEY
DOI: 10.1002/cac2.12110

Keywords

Hepatocellular carcinoma; Atezolizumab; Bevacizumab; Sorafenib; Cost-effectiveness

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.